Benzinga · Mar 5, 2026
NA
NASDAQ · NAGE
Niagen Bioscience Inc
Healthcare · Biotechnology
$3.00
Down-$0.04 (-1.32%)
Updated Sep 16, 2026, 11:08 AM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 529.91M
- P/E ratio
- 29.68
- Dividend yield
- 0.00%
- 52-week range
- $2.87 – $5.40
- Volume
- 573.55K
- Avg. volume
- 1.04M
Price performance
NAGE price history
1M range · 20 trading sessions · Daily adjusted prices
NAGE closed at $3.00 after 20 trading sessions, down 1.96% for the selected period.
- Last close
- $3.00
- Period change
- -1.96%
- Period low
- $3.00
- Period high
- $3.30
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $3.04 | $3.04 | $2.945 | $3.00 | 573.55K |
| Sep 14, 2026 | $3.035 | $3.10 | $3.03 | $3.04 | 420.76K |
| Sep 11, 2026 | $3.08 | $3.085 | $3.01 | $3.04 | 322.14K |
| Sep 10, 2026 | $3.03 | $3.065 | $3.00 | $3.035 | 276.57K |
| Sep 9, 2026 | $3.105 | $3.105 | $3.03 | $3.05 | 362.02K |
| Sep 8, 2026 | $3.16 | $3.18 | $3.10 | $3.10 | 531.9K |
| Sep 4, 2026 | $3.10 | $3.17 | $3.07 | $3.17 | 256.8K |
| Sep 3, 2026 | $3.19 | $3.235 | $3.10 | $3.11 | 242.25K |
| Sep 2, 2026 | $3.13 | $3.21 | $3.12 | $3.17 | 308.57K |
| Sep 1, 2026 | $3.11 | $3.15 | $3.0803 | $3.13 | 283K |
| Aug 31, 2026 | $3.27 | $3.275 | $3.12 | $3.13 | 477.59K |
| Aug 28, 2026 | $3.22 | $3.3025 | $3.20 | $3.29 | 498.29K |
| Aug 27, 2026 | $3.305 | $3.335 | $3.18 | $3.21 | 466.57K |
| Aug 26, 2026 | $3.27 | $3.32 | $3.22 | $3.30 | 388.62K |
| Aug 25, 2026 | $3.20 | $3.275 | $3.175 | $3.27 | 242.94K |
| Aug 24, 2026 | $3.21 | $3.28 | $3.19 | $3.21 | 415.75K |
| Aug 21, 2026 | $3.17 | $3.235 | $3.14 | $3.21 | 370.32K |
| Aug 20, 2026 | $3.17 | $3.18 | $3.0813 | $3.15 | 431.91K |
| Aug 19, 2026 | $3.06 | $3.26 | $3.06 | $3.17 | 806.65K |
| Aug 18, 2026 | $3.03 | $3.06 | $3.00 | $3.06 | 518.62K |
Latest NAGE news
The latest Smart Investors Daily articles mentioning NAGE.
Stock researchCompany · Overview
NAGE research
Overview
Company profile and research snapshot.
Company profile
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $14.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 11, 2026 | HC Wainwright & Co. | Buy | — |
| May 5, 2026 | Canaccord Genuity | Buy | — |
| Mar 31, 2026 | Canaccord Genuity | Buy | — |
| Mar 5, 2026 | Canaccord Genuity | Buy | — |
| Nov 5, 2025 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 5, 2026
Niagen Bioscience Rallies 18% After Hours: Here's Why
Niagen Bioscience Inc. surged in after-hours trading after reporting record 2025 results, while maintaining a cautious outlook for 2026.
Benzinga · Mar 5, 2026
Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion— Stock Jumps After-Hours (UPDATED)
NAD+ company Niagen Bioscience doubles profits in 2025, eyes acquisitions and new markets as the longevity market picks up momentum.
ChartMill · Mar 4, 2026
Niagen Bioscience Inc (NASDAQ:NAGE) Reports Q4 2025 Revenue Beat and Mixed Earnings
Niagen Bioscience (NAGE) reported strong 2025 sales growth, beating revenue estimates. While quarterly profit declined, full-year net income more than doubled. The company provided 2026 sales guidance and expanded its healthy aging portfolio.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
